Abstract
The novel immunosuppressant FTY720 has been demonstrated to elicit immunomodulating effects via interaction with the G-protein coupled receptor S1P(1). FTY720 induced agonism at the S1P(3) receptor, however, has been shown to result in mild bradycardia, a minor side-effect of initial FTY720 therapy. This report describes the synthesis of several potent 4(5)-phenylimidazole-based S1P(1) receptor agonists that are accompanied by poor agonist activity at S1P(3). For instance, compound 20 displayed an EC(50)=4.7+/-1.3 nM at the S1P(1) receptor and EC(50)=780+/-1.3 nM at the S1P(3) receptor using a [gamma-(35)S]GTP-binding assay as compared to phospho-FTY720 (S1P(1): EC(50)=1.3+/-1.3nM, S1P(3): EC(50)=2.0+/-2.4 nM).
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Benzimidazoles / chemical synthesis*
-
Benzimidazoles / pharmacology
-
Binding Sites
-
Bradycardia / drug therapy
-
CHO Cells
-
Cricetinae
-
Fingolimod Hydrochloride
-
Immunosuppressive Agents / chemical synthesis*
-
Immunosuppressive Agents / pharmacology
-
Lethal Dose 50
-
Lysophospholipids / chemical synthesis*
-
Lysophospholipids / pharmacology
-
Propylene Glycols / chemical synthesis*
-
Propylene Glycols / pharmacology
-
Receptors, Lysosphingolipid / agonists*
-
Receptors, Lysosphingolipid / metabolism
-
Sphingosine / analogs & derivatives*
-
Sphingosine / chemical synthesis
-
Sphingosine / pharmacology
-
Structure-Activity Relationship
Substances
-
Benzimidazoles
-
Immunosuppressive Agents
-
Lysophospholipids
-
Propylene Glycols
-
Receptors, Lysosphingolipid
-
sphingosine 1-phosphate
-
Fingolimod Hydrochloride
-
Sphingosine